SPIA
CUE icon

Steward Partners Investment Advisory’s Cue Biopharma CUE Stock Holding History

Steward Partners Investment Advisory’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10
Closed -$1K – 3384
2022
Q3 		$1K Hold
10
– – ﹤0.01% 3110
2022
Q2 		$1K Buy
+10
New +$1.17K ﹤0.01% 3099

Other funds holding CUE

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Steward Partners Investment Advisory's CUE Position: Q4 2022 in Review

Steward Partners Investment Advisory sold out of Cue Biopharma (CUE) in Q4 2022, closing a stake of 10 shares — an estimated $1K sold.

Steward Partners Investment Advisory first reported a position in CUE in Q2 2022 and held it in 2 quarters. The position peaked at $1K in Q3 2022. 61 funds tracked by Wall St. Rank hold CUE as of Q4 2022.

  • Steward Partners Investment Advisory reported no remaining Cue Biopharma position as of Q4 2022 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 10 Cue Biopharma shares in Q4 2022, an estimated $1K.
  • Steward Partners Investment Advisory first reported a position in Cue Biopharma in Q2 2022 and held it in 2 quarters.
  • Steward Partners Investment Advisory's Cue Biopharma position peaked at $1K in Q3 2022.
  • 61 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2022.

Based on Steward Partners Investment Advisory's 13F filing for Q4 2022, filed 15 Feb 2023.